Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease

被引：0
|
作者：
Catt, Heather [1 ]
Hughes, Dyfrig [2 ]
Bodger, Keith [1 ]
Kirkham, Jamie [1 ]
机构：
[1] Univ Liverpool, Liverpool, Merseyside, England
[2] Univ Bangor, Bangor, Gwynedd, Wales
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P143
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
    Keil, Radan
    Wasserbauer, Martin
    Zadorova, Zdena
    Hajer, Jan
    Drastich, Pavel
    Wohl, Pavel
    Benes, Marek
    Bojkova, Martina
    Svoboda, Pavel
    Konecny, Michal
    Falt, Premysl
    Vanasek, Tomas
    Pesta, Martin
    Pesek, Frantisek
    Bouchner, Ludek
    Kozeluhova, Jana
    Novotny, Ales
    Bartuskova, Lucie
    Spicak, Julius
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1062 - 1068
  • [32] Biosimilar infliximab versus originator in Crohn's disease anti-TNF-α naive and non-naive patients
    Kaniewska, Magdalena
    Rosolowski, Mariusz
    Moniuszko, Andrzej
    Rydzewska, Grazyna
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2021, 16 (03): : 207 - 212
  • [33] BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF CROHN'S DISEASE IN SIX CENTRAL EASTERN EUROPEAN COUNTRIES
    Brodszky, V
    Gulacsi, L.
    Balogh, O.
    Baji, P.
    Rencz, F.
    Pentek, M.
    VALUE IN HEALTH, 2014, 17 (07) : A364 - A364
  • [34] Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn's disease: The McGill Experience
    Al-Taweel, T.
    Strohl, M.
    Kopylov, U.
    Paradis-Suprenant, L.
    Almaimany, M.
    Martel, M.
    Bitton, A.
    Afif, W.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S369 - S369
  • [35] Everyone Isn't Average: Quantifying Heterogeneity in Crohn's Disease Patients' Benefit-Risk Tradeoff Preferences
    Bewtra, Meenakshi
    Johnson, F. Reed
    Reed, Shelby
    Scott, Frank I.
    Lewis, James D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 10 - 10
  • [36] The use of a novel anti-tumour necrosis factor α (Infliximab, Remicade™).: A new strategy for medical treatment of Crohn's disease -: Foreword
    Campieri, M
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (06): : 502 - 502
  • [37] Prediction of response to treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease.
    Andus, T
    Herfarth, H
    Obermeier, F
    Kuehbacher, T
    Mascheretti, S
    Thriene, W
    Schoelmerich, J
    Schreiber, S
    GASTROENTEROLOGY, 2001, 120 (05) : A621 - A621
  • [38] Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
    Robert Battat
    Christopher Ma
    Vipul Jairath
    Reena Khanna
    Brian G. Feagan
    Drug Safety, 2019, 42 : 617 - 632
  • [39] Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
    Strik, A.
    van de Vrie, W.
    van Megen, Y.
    Bloemsaat-Minekus, J.
    Rispens, T.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S420 - S420
  • [40] Crohn's disease patients' risk-benefit preferences:: Serious adverse event risks versus treatment efficacy
    Johnson, F. Reed
    Oezdemir, Semra
    Mansfield, Carol
    Hass, Steven
    Miller, David W.
    Siegel, Corey A.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2007, 133 (03) : 769 - 779
12345